Defining “True and Non-Misleading” for Pharmaceutical Promotion

The proposed “true and non-misleading” standard for pharmaceutical promotion, favored by industry as an alternative to restrictions on off-label marketing, is problematic because it lacks a clear, objective definition, and courts have permitted misleadingly narrow interpretations of “truth” that could undermine patient safety.